To foster a richer, more efficient and powerful product development process, DRW is opening our innovative and robust SAMBA point-of-care molecular platform to scientists and clinicians with expertise and interest in infectious disease, especially those relevant to resource-limited settings.
With your knowledge of a particular pathogen, and our SAMBA technology and product development expertise, we can rapidly develop prototype assays, validate them through clinical trials and deliver our innovations to the real world.
- Together we will encourage innovation, accelerate the pace of discovery, reducing information-sharing gaps, promote collaborations.
- By coming together and sharing our knowledge, we can develop useful assays for those who will benefit most.
To find out more about our open access program, contact us here, or email us at This email address is being protected from spambots. You need JavaScript enabled to view it.
